Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 5/16/25 → 8/16/25 |
Funding
- Regeneron Pharmaceuticals: $2.00
Study Start Up Costs Only: Quantum: A Phase 3, Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 mg Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion
- Clevenger, Leanne (PI)